The Foundation welcomes the decision to allow switching of age-related macular degeneration drugs Eylea and Lucentis.
Read MoreThe Foundation welcomes the decision to allow switching of age-related macular degeneration drugs Eylea and Lucentis.
Read MoreA powerful ‘How’s your macula?’ television advertisement has been produced by the Macular Degeneration Foundation.
Read MoreThere has been a big community response to the Foundation’s campaign to allow AMD drug “switching”.
Read MoreMacular Degeneration Foundation has announced, as part of World Sight Day activities, the winners of the mEYE World Photographic Competition 2012.
Read MoreThe Macular Degeneration Foundation has launched a new national awareness campaign that featured symptom recognition.
Read MoreInternational experts met in Sydney in 2012 to develop a road map for the management of wet age-related macular degeneration.
Read MoreWith a new treatment for wet AMD coming on the market, drug switching between Lucentis and Eylea should be allowed.
Read MoreResearch has revealed Australians significantly underestimate the role of family history in developing macular degeneration.
Read MoreMacular Degeneration Foundation believes a cap on the Medicare item number for the treatment of wet AMD should have minimal impact on patients.
Read More